We have contributed to the development of the first generation cationic liposome. One such formulation, DC-chol/DOPE liposome, was the first to be tested in human clinical trials in 1992.

These findings have important implications regarding the intravascular delivery of cationic liposome-DNA complexes for gene therapy. For most cationic liposome-DNA formulations, access is limited ...